Union Ministry of Health Proposes Incorporation of Good Storage and Distribution Practices into Drugs Rules, 1945
FlashcardsQuick reviseKey facts. One by one.Start →In this note
- At a Glance
- Why in the News
- Background & Evolution
- Core Static Facts
- Multi-Dimensional Analysis
- Recent Developments (last 12–18 months)
- Prelims Hooks
- Why a Good Rule Can Still Fail at the Inspector's Desk
- What the Drug-Quality Numbers Tell Us About This Rule
- What Should Follow Once the Rule Is Notified
- Anchors for Answers
- Mains Relevance
- Related Topics to Study Next
- NCERT Concepts to Revise
- Common Errors / Trap Areas
1. At a Glance
- The Union Ministry of Health and Family Welfare has proposed adding Good Storage and Distribution Practices (GSDP) for pharmaceuticals to the Drugs Rules, 1945 [1].
- GSDP are quality standards for how medicines are procured, stored, distributed and transported after they are made. The goal is to keep their quality, safety, efficacy and integrity intact all the way from the manufacturer or importer to the patient [1].
- Why it matters for UPSC: India's drug-quality regulation has focused on the manufacturing stage. This proposal extends it to the distribution stage, and puts in the Rules what had only been CDSCO guidance [1].
- The proposal follows a global benchmark: WHO's "Good storage and distribution practices for medical products", published as Annex 7 of WHO Technical Report Series (TRS) No. 1025 [2].
2. Why in the News
- 19 November 2026: PIB released the proposal to add GSDP to the Drugs Rules, 1945 [1].
- Objections and suggestions have been invited from the public and stakeholders. The proposal is at the consultation stage and has not yet been notified as final [1].
- The release describes the amendment as an important step towards strengthening India's pharmaceutical quality-management system [1].
3. Background & Evolution
- 1945: The Drugs Rules were framed. These are the Rules now proposed to be amended [1].
- 17 June 2020: WHO published TRS 1025, Annex 7: Good storage and distribution practices for medical products [2].
- WHO's distribution-guidelines page lists related guidance alongside it: shelf-life, import procedures, and model guidance for temperature-sensitive products [3].
- Predecessor in India: CDSCO developed GSDP guidance. The current proposal builds on it and gives its requirements a place in the Rules [1].
- 19 November 2026: The Health Ministry proposed adding GSDP to the Drugs Rules, 1945 [1].
- Not covered by any whitelisted source, so left out of this timeline: the dates of earlier CDSCO draft GDP guidelines, and recommendations by the Drugs Technical Advisory Board (DTAB) or Drugs Consultative Committee (DCC). Check these on cdsco.gov.in before using them.
4. Core Static Facts
| Item | Fact |
|---|---|
| Proposing ministry | Union Ministry of Health and Family Welfare [1] |
| Rules to be amended | Drugs Rules, 1945 [1] |
| Source guidance | CDSCO's GSDP guidance [1] |
| Enforcement bodies | Central and State drug-control authorities, for oversight, inspection and enforcement [1] |
| Scope of GSDP | Procurement, purchasing, storage, distribution, transportation, documentation, record-keeping [1] |
| Entities covered | Manufacturers, importers, wholesalers, distributors, stockists and other entities in the distribution process [1] |
| Risks targeted | Deterioration, contamination, mix-ups, falsification, diversion, unauthorised distribution [1] |
| Core principle | Quality established at manufacture must be maintained until the product reaches the patient [1] |
| Global benchmark | WHO TRS No. 1025, Annex 7 (17 June 2020) [2] |
| WHO assessment tool | WHO GSDP Warehouse Rapid Assessment Tool. WHO's eManual applies GSDP with additional controls for pharmaceuticals, vaccines and medical devices [4] |
| Status | Proposal; public objections and suggestions invited [1] |
Key terms:
- Traceability: documentation and records that let a product be followed through the distribution chain [1].
- Diversion: movement of products outside authorised channels [1].
- Falsification: introduction of fake medicines into the supply chain [1].
5. Multi-Dimensional Analysis
Legal / Regulatory
- The change turns guidance (CDSCO's GSDP) into rules (the Drugs Rules, 1945). Compliance moves from best practice to an enforceable legal requirement [1].
- A legal basis in the Rules is expected to strengthen inspection and enforcement by drug-control authorities [1].
Administrative / Federal
- The release names both Central and State drug-control authorities as responsible for oversight, inspection and enforcement [1].
- Implementation risk: the rules cover many wholesalers, distributors and stockists across the country, so inspection capacity will decide how well they work. (Analytical inference.)
Public Health / Social
- Poor storage or transport can degrade a medicine after it leaves the factory. GSDP protects efficacy at the point of supply to the patient [1].
- WHO's framework applies additional controls for vaccines and temperature-sensitive products [3][4]. This links GSDP to immunisation cold chains. (Linkage is analytical.)
Ethical / Governance
- Documentation and record-keeping raise traceability and accountability across the supply chain [1].
- The rules directly target falsification and diversion, which are integrity failures that hurt patients and public trust [1].
Economic / Trade
- Aligning with WHO norms [2] can support the global credibility of Indian medicines and exports. (Analytical inference.)
- Smaller stockists and distributors may face compliance costs, for example for temperature-controlled storage and records. (Analytical inference.)
Scientific / Technological
- Keeping products within specified environmental conditions during storage and transport [1] requires monitoring. This opens room for digital track-and-trace and temperature logging. (Analytical inference.)
6. Recent Developments (last 12–18 months)
- 19 Nov 2026: The Health Ministry proposed adding GSDP to the Drugs Rules, 1945, and invited objections and suggestions from the public and stakeholders [1].
- No other dated development from a whitelisted source could be confirmed within the 3-search limit.
7. Prelims Hooks
- GSDP stands for Good Storage and Distribution Practices [1].
- GSDP is proposed to be added to the Drugs Rules, 1945 [1].
- Proposing ministry: Ministry of Health and Family Welfare [1].
- The proposed framework builds on GSDP guidance developed by CDSCO [1].
- GSDP covers procurement, purchasing, storage, distribution, transportation, documentation and record-keeping [1].
- Risks targeted: deterioration, contamination, mix-ups, falsification, diversion, unauthorised distribution [1].
- Enforcement lies with both Central and State drug-control authorities [1].
- Entities covered include manufacturers, importers, wholesalers, distributors and stockists [1].
- GSDP addresses post-manufacture quality, i.e. from the manufacturer or importer to the patient [1].
- The WHO benchmark is TRS No. 1025, Annex 7, published 17 June 2020 [2].
- WHO has a GSDP Warehouse Rapid Assessment Tool [4].
- WHO's GSDP framework applies additional controls for pharmaceuticals, vaccines and medical devices [4].
8. Why a Good Rule Can Still Fail at the Inspector's Desk
- The rule adds work, but not inspectors
- GSDP brings every wholesaler, distributor and stockist under inspection [1]. That is many thousands of new premises to check.
- India's drug control was already short of people. In 2003 the Mashelkar Committee found too few trained staff at the Centre and in the States, and uneven enforcement from State to State [7].
- A Rajya Sabha Standing Committee heard the same complaint in 2007: too few drug inspectors, weak control infrastructure and too few testing labs [6].
-
The proposal says nothing about extra staff. Without new posts, the same inspectors will simply spread thinner.
-
Enforcement so far has looked at factories, not warehouses
- Recent enforcement has meant risk-based inspection of manufacturing units: 905 units inspected and 694 actions taken, such as stop-production orders and cancelled licences [5].
- A storage failure happens after the drug leaves the factory. It is caught only if someone takes a sample from the shop or the warehouse.
-
Mashelkar asked States to take more samples of drugs sold in the market, and to match inspector numbers to their workload [7]. GSDP will work only if States actually do this.
-
One rule, many different State machines
- Central and State authorities share enforcement [1]. In practice the States carry most of the work at the warehouse level.
- Mashelkar's main finding was that weak State capacity creates uneven quality across the country [7]. So a stockist in a well-staffed State and one in a weak State will face very different levels of checking under the same rule.
9. What the Drug-Quality Numbers Tell Us About This Rule
- The problem is real, but it is hard to measure
- A Parliamentary Standing Committee (2013) put NSQ drugs (Not of Standard Quality: real drugs that fail a quality test) at 7–8%, and spurious drugs (fakes) at 0.5% [7].
-
Across low- and middle-income countries, WHO estimates that at least 1 in 10 medical products is substandard or falsified. Countries spend about US$30.5 billion a year on them [8].
-
A failed test does not show where the drug went bad
- CDSCO publishes NSQ results as monthly drug alerts and orders the manufacturer to recall the product [5].
- But a medicine can be made correctly and then spoil in a hot warehouse or a truck. The test result alone cannot tell factory failure from storage failure.
-
GSDP's records of temperature, batch and movement [1] could finally let a regulator find out where the drug went bad, and blame the right party.
-
The supply chain is changing faster than the rules
- WHO says falsified medicines are growing as supply chains become more complex, and online sales add to the problem [8].
- The proposal names manufacturers, importers, wholesalers, distributors and stockists, and adds "other entities" [1]. Online pharmacies and delivery partners are not named. Whether they are covered will depend on how the final Rules are worded.
10. What Should Follow Once the Rule Is Notified
- States should create inspector posts based on workload
- Mashelkar recommended linking inspector numbers to the number of inspections needed [7].
-
In 2007 the Centre created 62 new Drug Inspector posts to meet a shortfall [6]. GSDP needs a similar step, but at State level, where the warehouses are.
-
Drug controllers should sample at the distribution stage
- Today's sampling and recalls are built around the manufacturer [5].
-
Central and State drug controllers should take some samples from stockists and wholesalers. Then NSQ data can show whether quality is being lost after the factory.
-
CDSCO should give small stockists a simple self-check first
- WHO's GSDP Warehouse Rapid Assessment Tool lets a warehouse measure itself against GSDP quickly [4].
-
A similar Indian checklist would let a small stockist find and fix gaps before the first inspection. This could come with a phased deadline, instead of facing penalties on day one.
-
The Health Ministry should state clearly who is covered
- WHO points to online sales as a growing route for falsified medicines [8].
- The final notification should say plainly whether online pharmacies and couriers count as "entities in the distribution process" [1].
11. Anchors for Answers
- Data: At least 1 in 10 medical products in low- and middle-income countries is substandard or falsified; about US$30.5 billion is spent on them each year (WHO) [8]
- Data: 7–8% of drugs NSQ and 0.5% spurious, as estimated by a Parliamentary Standing Committee (2013) [7]
- Data: 905 drug units inspected and 694 enforcement actions taken under risk-based inspection [5]
- Report/Committee: Mashelkar Committee (2003): too few trained staff, uneven State enforcement, inspector numbers should match workload [7]; Rajya Sabha Standing Committee on the Drugs and Cosmetics (Amendment) Bill, 2007 [6]
- Comparison: WHO TRS 1025 Annex 7 and the GSDP Warehouse Rapid Assessment Tool, a global standard plus a self-check tool [2][4]
12. Mains Relevance
- GS-II: Health; government policies and interventions; statutory, regulatory and quasi-judicial bodies (CDSCO, State drug controllers); Centre–State coordination.
- GS-III: Pharmaceutical industry; supply-chain and logistics infrastructure; export competitiveness.
- GS-IV (case studies): Integrity in public health supply chains; accountability for falsified drugs.
- Possible question stems: 1. "Drug quality is not only made in the factory but also lost in the warehouse." Examine the significance of incorporating Good Storage and Distribution Practices into the Drugs Rules, 1945. 2. Discuss the challenges of enforcing pharmaceutical distribution-stage regulation in a federal setup where drug control is shared between the Centre and the States. 3. How can traceability and supply-chain regulation curb the threat of falsified and diverted medicines in India? Suggest measures.
13. Related Topics to Study Next
- Revised Schedule M (GMP) of the Drugs Rules, 1945: the manufacturing-stage counterpart to GSDP's distribution stage.
- CDSCO and DCGI: structure and powers of the national drug regulator.
- Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committee (DCC): the statutory advisory bodies that shape amendments to the Drugs Rules.
- WHO prequalification and the WHO Expert Committee on Specifications for Pharmaceutical Preparations: the origin of the TRS norms.
- Cough-syrup contamination incidents and drug-quality alerts (NSQ / spurious drugs): the practical stakes of regulating quality.
- Cold chain and eVIN under Universal Immunisation Programme: temperature-controlled distribution in practice.
- Track-and-trace / QR-code mandates for APIs and medicines: traceability tools.
- Jan Aushadhi (PMBJP) supply chain: public procurement and distribution of generic medicines.
14. NCERT Concepts to Revise
- Drugs Rules, 1945 (Polity): The rules being amended to add GSDP; know what they cover and how they differ from the parent Act.
- Central Drugs Standard Control Organisation (Polity): CDSCO developed the GSDP guidance, and Central and State drug controllers share enforcement of it.
- Schedule M (Economy): Manufacturing-stage GMP counterpart in the same Rules; GSDP extends quality control to storage and distribution.
- Substandard and falsified medical products (Economy): GSDP targets falsification and quality loss, and the note uses WHO's 1-in-10 estimate.
- World Health Organization (Polity): WHO's TRS 1025 Annex 7 is the global benchmark on which India's GSDP proposal is modelled.
- Drugs Technical Advisory Board (Polity): Statutory expert body that advises the Centre on amendments to the Drugs Rules, such as this one.
- Drugs Consultative Committee (Polity): Statutory body of Central and State drug controllers that advises on uniform enforcement, which matters for GSDP rollout.
- Cold chain (Economy): Temperature-controlled storage and transport of vaccines and medicines is the practical core of GSDP.
- Supply chain (Economy): GSDP regulates the whole medicine supply chain from manufacturer to patient, including traceability.
- WHO Prequalification (Economy): Related WHO quality-assurance programme that checks manufacturers against international standards, alongside the TRS norms.
- PM Bhartiya Janaushadhi Pariyojana (Economy): Public generic-medicine procurement and distribution network where storage and distribution quality directly matters.
- QR code (Economy): QR-code track-and-trace is a traceability tool against falsified and diverted medicines.
15. Common Errors / Trap Areas
- Rules vs Act: GSDP goes into the Drugs Rules, 1945, not into the parent Act directly [1]. Don't mix up the year of the Rules (1945) with the year of the Act (1940; not confirmed in the whitelisted sources).
- GSDP vs GMP: GMP (Schedule M) governs manufacturing. GSDP governs storage and distribution after manufacture [1].
- Proposed, not final: As of 19 Nov 2026 this is a proposal inviting objections, not a notified rule [1].
- CDSCO's role: CDSCO developed the guidance, while the Ministry of Health proposes the amendment to the Rules [1].
- Enforcement is not Centre-only: both Central and State authorities are named [1].
- WHO document number: GSDP is TRS 1025, Annex 7 (2020) [2]. Don't mix it up with other TRS annexes on shelf-life or temperature-sensitive products [3].
Sources
- 1Press Release Page | Press Information Bureau (supplied digest of the 19 Nov 2026 release)pib.gov.in · tier 1
- 2TRS 1025 – Annex 7: Good storage and distribution practices for medical productswho.int · tier 2
- 3WHO Health products policy and standards – Distribution guidelineswho.int · tier 2
- 4WHO eManual – GSDP requirements / Warehouse Rapid Assessment Toolemanual.who.int · tier 2
- 5Steps taken to Prevent Sale of Adulterated Drugs (PIB)pib.gov.in · tier 1
- 6Rajya Sabha Department-related Parliamentary Standing Committee Report on the Drugs and Cosmetics (Amendment) Bill, 2007 (PRS)prsindia.org · tier 1
- 7Demand for Grants 2018-19 Analysis: Health and Family Welfare (PRS)prsindia.org · tier 1
- 8Substandard and falsified medical products – WHO Fact Sheetwho.int · tier 2